MDT

SEC source: 0001127602-21-014591 · form4.xml · nonDerivative · entry 1

ARNOLD CRAIG · CIK 0001188578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,620

F1 · balance_after: This balance increased by 37 shares due to exempt transactions such as dividend reinvestment.

SEC source: 0001127602-21-014588 · form4.xml · nonDerivative · entry 1

HOGAN RANDALL J · CIK 0001189049 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,348

F1 · balance_after: This balance increased by 27 shares due to exempt transactions such as dividend reinvestment.

SEC source: 0001127602-21-014592 · form4.xml · nonDerivative · entry 1

ANDERSON RICHARD H · CIK 0001200334 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,716

F1 · balance_after: This balance increased by 469 shares due to exempt transactions such as dividend reinvestment.

SEC source: 0001127602-21-014589 · form4.xml · nonDerivative · entry 1

Goldsmith Andrea Jo · CIK 0001730514 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,651

F1 · balance_after: This balance increased by 38 shares due to exempt transactions such as dividend reinvestment.

F2 · balance_after: Includes a total of 90 shares acquired by the reporting person's investment advisor in a managed account that were not previously reported due to inadvertent administrative oversight, as follows: 5 shares on August 29, 2017; 3 shares on October 3, 2017; 7 shares on November 9, 2017; 2 shares on February 5, 2018; 7 shares on April 2, 2019; 6 shares on April 10, 2019; 4 shares on April 18, 2019; 7 shares on April 24, 2019; 2 shares on May 13, 2019; 5 shares on June 4, 2019; 10 shares on March 9, 2020; 5 shares on June 12, 2020; 5 shares on June 15, 2020; 6 shares on June 22, 2020; 8 shares on September 8, 2020; and 8 shares on February 25, 2021.

SEC source: 0001127602-21-014586 · form4.xml · nonDerivative · entry 1

NABEL ELIZABETH G · CIK 0001619929 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,019

F1 · balance_after: This balance increased by 37 shares due to exempt transactions such as dividend reinvestment.

SEC source: 0001127602-21-013399 · form4.xml · derivative · entry 6

Martha Geoffrey · CIK 0001560409 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,173

Underlying: Ordinary Shares · 9,308 shares

Expires 2023-07-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F4 · derivative.exercise_date: This option to purchase 1,808 Medtronic ordinary shares for $55.32 per share, which was partially vested at the effective time of the Covidien acquisition, represents the conversion of an option to purchase 1,808 Medtronic Inc. common stock shares for $55.32 per share. This Medtronic plc stock option has the same terms and conditions as the original Medtronic Inc. stock option.

F5 · derivative.exercise_date: This option to purchase 20,481 Medtronic ordinary shares for $55.32 per share, which was partially vested at the effective time of the Covidien acquisition, represents the conversion of an option to purchase 20,481 Medtronic Inc. common stock shares for $55.32 per share. This Medtronic plc stock option has the same terms and conditions as the original Medtronic Inc. stock option.

SEC source: 0001127602-21-013399 · form4.xml · derivative · entry 5

Martha Geoffrey · CIK 0001560409 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 2,404 shares

Expires 2022-10-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: This option to purchase 2,404 Medtronic ordinary shares for $41.60 per share, which was partially vested at the effective time of the Covidien acquisition, represents the conversion of an option to purchase 2,404 Medtronic Inc. common stock shares for $41.60 per share. This Medtronic plc stock option has the same terms and conditions as the original Medtronic Inc. stock option.

SEC source: 0001127602-21-013399 · form4.xml · nonDerivative · entry 4

Martha Geoffrey · CIK 0001560409 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,938

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001127602-21-013399 · form4.xml · nonDerivative · entry 3

Martha Geoffrey · CIK 0001560409 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,246

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001127602-21-013399 · form4.xml · nonDerivative · entry 2

Martha Geoffrey · CIK 0001560409 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,938

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001127602-21-013399 · form4.xml · nonDerivative · entry 1

Martha Geoffrey · CIK 0001560409 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,342

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · balance_after: This balance increased by 844 shares due to exempt transactions such as dividend reinvestment.

SEC source: 0001127602-21-010841 · form4.xml · nonDerivative · entry 1

PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,556

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · balance_after: This balance increased by 291 shares due to exempt transactions such as dividend reinvestment.

SEC source: 0001127602-21-009239 · form4.xml · derivative · entry 3

TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 7,168 shares

Expires 2021-08-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option to purchase 7,168 Medtronic ordinary shares for $34.88 per share, which was partially vested at the effective time of the Covidien acquisition, represents the conversion of an option to purchase 7,168 Medtronic Inc. common stock shares for $34.88 per share. This Medtronic plc stock option has the same terms and conditions as the original Medtronic Inc. stock option.

SEC source: 0001127602-21-009239 · form4.xml · nonDerivative · entry 2

TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,797

SEC source: 0001127602-21-009239 · form4.xml · nonDerivative · entry 1

TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,965

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This balance increased by 321 shares due to exempt transactions such as dividend reinvestment.

SEC source: 0001127602-21-003781 · form4.xml · derivative · entry 3

Salmon Sean · CIK 0001792380 · EVP & Group President Diabetes

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,947

Underlying: Performance Share Units · 4,947 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock.

F4 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 4,947 shares will be issued. The actual number of shares to be issued could range from a low of 990 at minimum performance to a high of 9,894 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares.

F5 · derivative.exercise_date: Vests on February 1, 2024.

F5 · derivative.expiration_date: Vests on February 1, 2024.

SEC source: 0001127602-21-003781 · form4.xml · derivative · entry 2

Salmon Sean · CIK 0001792380 · EVP & Group President Diabetes

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,314

Underlying: Ordinary Shares · 16,314 shares

Expires 2031-02-01

F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant.

SEC source: 0001127602-21-003781 · form4.xml · nonDerivative · entry 1

Salmon Sean · CIK 0001792380 · EVP & Group President Diabetes

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,007

F1 · balance_after: This balance increased by 128 shares due to exempt transactions such as dividend reinvestment.

SEC source: 0001127602-20-032568 · form4.xml · nonDerivative · entry 1

Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,150

F1 · price: The price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.87 to $115.01, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes to this Form 4.

F2 · balance_after: This balance increased by 110 shares due to exempt transactions such as dividend reinvestment.

SEC source: 0001127602-20-032287 · form4.xml · nonDerivative · entry 1

Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,543

SEC source: 0001127602-20-032108 · form4.xml · nonDerivative · entry 3

WHITE ROBERT JOHN · CIK 0001726709 · EVP & Pres. Medical Surgical

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,922

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.43 to $115.52, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001127602-20-032108 · form4.xml · nonDerivative · entry 2

WHITE ROBERT JOHN · CIK 0001726709 · EVP & Pres. Medical Surgical

10b5-1 filing: Not disclosed

Ownership: Indirect · Family Trust

Disclosed balance after: 1,500

F1 · ownership.nature: These securities are owned by the White Family Legacy Trust. The reporting person is the co-trustee. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-032108 · form4.xml · nonDerivative · entry 1

WHITE ROBERT JOHN · CIK 0001726709 · EVP & Pres. Medical Surgical

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,852

SEC source: 0001127602-20-031597 · form4.xml · nonDerivative · entry 1

PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,897

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · balance_after: This balance increased by 201 shares due to exempt transactions such as dividend reinvestment.

SEC source: 0001127602-20-028647 · form4.xml · derivative · entry 5

Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 797 shares

Expires 2024-07-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · derivative.exercise_date: This option became exercisable on June 29, 2018, upon achievement of a pre-specified cash Earnings Per Share Growth Rate for fiscal years 2016 through 2018.

SEC source: 0001127602-20-028647 · form4.xml · derivative · entry 4

Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 19,918 shares

Expires 2024-07-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · derivative.exercise_date: This option became exercisable on June 29, 2018, upon achievement of a pre-specified cash Earnings Per Share Growth Rate for fiscal years 2016 through 2018.

SEC source: 0001127602-20-028647 · form4.xml · nonDerivative · entry 3

Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,148

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001127602-20-028647 · form4.xml · nonDerivative · entry 2

Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,863

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001127602-20-028647 · form4.xml · nonDerivative · entry 1

Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,066

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001127602-20-028281 · form4.xml · nonDerivative · entry 1

Liddicoat John R · CIK 0001752060 · EVP & President of Americas

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,989

F1 · balance_after: This balance increased by 290 shares due to exempt transactions such as dividend reinvestment and employee stock purchase plan.

SEC source: 0001127602-20-028284 · form4.xml · nonDerivative · entry 1

WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,352

F1 · balance_after: This balance increased by 159 shares due to exempt transactions such as dividend reinvestment.

SEC source: 0001127602-20-028283 · form4.xml · nonDerivative · entry 1

Wall Brett A. · CIK 0001473812 · EVP & Group Pres Restora Thera

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,715

F1 · balance_after: This balance increased by 88 shares due to exempt transactions such as dividend reinvestment.

SEC source: 0001127602-20-028274 · form4.xml · nonDerivative · entry 1

COYLE MICHAEL J · CIK 0001233311 · EVP & Group Pres, Cardiac&Vasc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 190,390

F1 · balance_after: This balance increased by 220 shares due to exempt transactions such as dividend reinvestment.

SEC source: 0001127602-20-028279 · form4.xml · nonDerivative · entry 1

Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,009

F1 · balance_after: This balance increased by 281 shares due to exempt transactions such as dividend reinvestment.

SEC source: 0001127602-20-028280 · form4.xml · nonDerivative · entry 1

Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,148

F1 · balance_after: This balance increased by 160 shares due to exempt transactions such as dividend reinvestment.

SEC source: 0001127602-20-028282 · form4.xml · nonDerivative · entry 1

Salmon Sean · CIK 0001792380 · EVP & Group President Diabetes

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,900

F1 · balance_after: This balance increased by 79 shares due to exempt transactions such as dividend reinvestment.

SEC source: 0001127602-20-031212 · form4.xml · nonDerivative · entry 2

ISHRAK OMAR · CIK 0001523102 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · Joint Revocable Trust

Disclosed balance after: 8,650

F1 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's children. The reporting person's spouse and the reporting person are co-trustees of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001127602-20-031212 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · 2019 GRAT

Disclosed balance after: 9,532

SEC source: 0001127602-20-031207 · form4.xml · nonDerivative · entry 2

HOGAN RANDALL J · CIK 0001189049 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Family Limited Partnership

Disclosed balance after: 36,798

F2 · ownership.nature: The reporting person transferred the shares noted in column 4 to a family limited partnership, RSEK Ventures LLP. The reporting person is the sole manager of the general partners of RSEK Ventures, LLP.

SEC source: 0001127602-20-031207 · form4.xml · nonDerivative · entry 1

HOGAN RANDALL J · CIK 0001189049 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,747

F1 · balance_after: This balance increased by 10 shares due to exempt transactions such as dividend reinvestment.

SEC source: 0001127602-20-026956 · form4.xml · derivative · entry 1

Liddicoat John R · CIK 0001752060 · EVP & President of Americas

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,742

Underlying: Performance Share Units · 8,742 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock.

F2 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 8,742 shares will be issued. The actual number of shares to be issued could range from a low of 1,749 at minimum performance to a high of 17,484 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares.

F3 · derivative.exercise_date: Vests on August 3, 2023.

F3 · derivative.expiration_date: Vests on August 3, 2023.

SEC source: 0001127602-20-026963 · form4.xml · derivative · entry 1

WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,563

Underlying: Performance Share Units · 16,563 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock.

F2 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 16,563 shares will be issued. The actual number of shares to be issued could range from a low of 3,313 at minimum performance to a high of 33,126 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares.

F3 · derivative.exercise_date: Vests on August 3, 2023.

F3 · derivative.expiration_date: Vests on August 3, 2023.

SEC source: 0001127602-20-026960 · form4.xml · derivative · entry 1

Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,582

Underlying: Performance Share Units · 10,582 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock.

F2 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 10,582 shares will be issued. The actual number of shares to be issued could range from a low of 2,117 at minimum performance to a high of 21,164 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares.

F3 · derivative.exercise_date: Vests on August 3, 2023.

F3 · derivative.expiration_date: Vests on August 3, 2023.

SEC source: 0001127602-20-026962 · form4.xml · derivative · entry 1

Wall Brett A. · CIK 0001473812 · EVP & Group Pres Restora Thera

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,723

Underlying: Performance Share Units · 14,723 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock.

F2 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 14,723 shares will be issued. The actual number of shares to be issued could range from a low of 2,945 at minimum performance to a high of 29,446 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares.

F3 · derivative.exercise_date: Vests on August 3, 2023.

F3 · derivative.expiration_date: Vests on August 3, 2023.

SEC source: 0001127602-20-026952 · form4.xml · derivative · entry 1

COYLE MICHAEL J · CIK 0001233311 · EVP & Group Pres, Cardiac&Vasc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,164

Underlying: Performance Share Units · 21,164 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock.

F2 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 21,164 shares will be issued. The actual number of shares to be issued could range from a low of 4,233 at minimum performance to a high of 42,328 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares.

F3 · derivative.exercise_date: Vests on August 3, 2023.

F3 · derivative.expiration_date: Vests on August 3, 2023.

SEC source: 0001127602-20-026961 · form4.xml · derivative · entry 1

TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,882

Underlying: Performance Share Units · 12,882 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock.

F2 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 12,882 shares will be issued. The actual number of shares to be issued could range from a low of 2,577 shares at minimum performance to a high of 25,764 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares.

F3 · derivative.exercise_date: Vests on August 3, 2023.

F3 · derivative.expiration_date: Vests on August 3, 2023.

SEC source: 0001127602-20-026953 · form4.xml · derivative · entry 1

Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,723

Underlying: Performance Share Units · 14,723 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock.

F2 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 14,723 shares will be issued. The actual number of shares to be issued could range from a low of 2,945 at minimum performance to a high of 29,446 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares.

F3 · derivative.exercise_date: Vests on August 3, 2023.

F3 · derivative.expiration_date: Vests on August 3, 2023.

SEC source: 0001127602-20-026951 · form4.xml · nonDerivative · entry 3

ISHRAK OMAR · CIK 0001523102 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 566,932

SEC source: 0001127602-20-026951 · form4.xml · nonDerivative · entry 2

ISHRAK OMAR · CIK 0001523102 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · 2018 GRAT

Disclosed balance after: 0

SEC source: 0001127602-20-026951 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 561,032

F1 · price: The price in Column 4 is a weighted average price and has been rounded to two decimals. The share were sold in multiple transactions at prices ranging from $108.395 to $108.397, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.